Kelley Hasenauer, APRN
Family · North Platte, NENPI 1780699132
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 204 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AbbVie at 50.2% of the total. Among family clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 204 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Astellas Pharma US Inc$255
- Lilly USA, LLC$176
- Otsuka America Pharmaceutical, Inc.$145
- Novo Nordisk$143
- Pfizer$138
- plus $938 from 24 others
What the payments were for
- Food & beverage$3,52998%
- Education$742%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 113 | $1,807 |
| Astellas Pharma US Inc | 11 | $255 |
| Lilly USA, LLC | 11 | $176 |
| Otsuka America Pharmaceutical, Inc. | 8 | $145 |
| Novo Nordisk | 7 | $143 |
| Pfizer | 6 | $138 |
| Ascend Therapeutics US, LLC | 6 | $126 |
| Johnson & Johnson | 1 | $114 |
| IBSA Pharma Inc. | 4 | $76 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $67 |
| Myovant Sciences Inc. | 3 | $56 |
| Lundbeck LLC | 3 | $44 |
| AstraZeneca | 3 | $43 |
| Optinose US, Inc. | 2 | $40 |
| Bayer | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Biogen | 1 | $29 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Organon | 3 | $22 |
| Biowound Solutions, Inc. | 1 | $20 |
| Mayne Pharma Commercial LLC | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Vivus LLC | 1 | $17 |
| Urovant Sciences Inc | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,602 in reported general payments places this provider in the 90th percentile of 809 family providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 61 | $90,681 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 36 | $58,059 |
| FarxigaDapagliflozin Propanediol | 46 | $45,373 |
| MounjaroTirzepatide | 34 | $42,387 |
| JardianceEmpagliflozin | 53 | $36,946 |
| EliquisApixaban | 31 | $31,917 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 31 | $26,547 |
| TrulicityDulaglutide | 19 | $25,528 |
| MyrbetriqMirabegron | 35 | $24,304 |
| XareltoRivaroxaban | 16 | $9,688 |
| EstringEstradiol | 13 | $6,766 |
| Estradiol | 60 | $3,714 |
| Levothyroxine Sodium | 270 | $3,223 |
| Duloxetine Hcl | 86 | $3,071 |
| Atorvastatin Calcium | 202 | $2,454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6 | $143 | $148,74097 claims |
| Lilly USA, LLCMounjaro, Trulicity | $176 | $67,91653 claims |
| AstraZenecaFarxiga | $43 | $45,37346 claims |
| PfizerEliquis, Estring | $138 | $38,68344 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $15 | $26,54731 claims |
| Astellas Pharma US IncMyrbetriq | $255 | $24,30435 claims |
| Johnson & JohnsonXarelto | $114 | $9,68816 claims |
| AbbVieSynthroid | $1,807 | $1,10023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 809 family providers in Nebraska.
Other family in North Platte
- Chantel CollierFriend$257K
- Stephanie SimonOmaha$157K
- Rebecca NewberryOmaha$156K
- Michelle BrtekzwienerNorfolk$59K
- Angela CraigOmaha$35K
- Laura FalconeOmaha$26K
- Ladeana SmedlundBoys Town$21K
- Brittany MatneyOmaha$14K
- Patricia TeeterWahoo$13K
- Mary MetzLincoln$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.